Schering Compliance Appointment Reflects Hassan’s Pursuit Of GMP Closure
This article was originally published in The Tan Sheet
Executive Summary
Schering-Plough's appointment of Brent Saunders as senior VP-global compliance & business practices is indicative of CEO Fred Hassan's aggressive strategy of addressing the firm's compliance issues
You may also be interested in...
Schering Continues To Feel Symptoms From Claritin Switch With Net Loss
Sales of Schering-Plough's OTC Claritin (loratadine) allergy drug rebounded from a poor second quarter but the impact of the switch from Rx status continued to drag down the firm's overall earnings
Schering Continues To Feel Symptoms From Claritin Switch With Net Loss
Sales of Schering-Plough's OTC Claritin (loratadine) allergy drug rebounded from a poor second quarter but the impact of the switch from Rx status continued to drag down the firm's overall earnings
Schering Continues To Feel Symptoms From Claritin Switch With Net Loss
Sales of Schering-Plough's OTC Claritin (loratadine) allergy drug rebounded from a poor second quarter but the impact of the switch from Rx status continued to drag down the firm's overall earnings